Who does this study affect: People with newly diagnosed, advanced, high-grade epithelial ovarian cancer that does not have a BRCA mutation. Adding durvalumab and olaparib to standard treatment delays cancer growth for people with advanced ovarian cancerĪdding durvalumab and olaparib to standard treatment delays cancer growth for people with advanced ovarian cancer.One of the studies that will be presented today explores improving treatment for advanced ovarian cancer: From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world will gather to discuss the latest research and how to ensure that all people receive the cancer care they need. The theme of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting is Partnering With Patients: The Cornerstone of Cancer Care and Research.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |